Abstract
Background:
The purpose of this study was to explore whether newer galenic formulations with lower treatment burdens are associated with better patient compliance and persistence compared with older more burdensome modalities.
Methods:
Data from the IMS Disease Analyzer database were analyzed retrospectively for two pairs of analogs (alendronate sodium once daily vs once weekly and immediate-release vs extended-release methylphenidate) and one pair of drugs with similar indications but important differences in convenience and dosing instructions (desferrioxamine vs deferasirox). Compliance was calculated as the sum of prescription durations for all prescriptions for each patient over 1 year. Persistence was calculated as the time between first and last prescriptions over 2 years (1 year for deferasirox and desferrioxamine). Data from Germany and the UK were available and used for analysis.
Results:
Incremental improvements in compliance were +30% in the UK and +26% in Germany for alendronate once weekly vs once daily, +14% in the UK and +19% in Germany for extended-release vs immediate-release methylphenidate, and +15% in Germany for desferrioxamine vs deferasirox. Incremental improvements in persistence were +9 months in the UK and +8 months in Germany for alendronate once weekly vs once daily, +4 months in the UK and +3 months in Germany for extended-release vs immediate-release methylphenidate, and +2 months in Germany for deferasirox vs desferrioxamine.
Conclusion:
The new formulations that we evaluated were associated with better compliance and persistence compared with older formulations. Despite the fact that some sources of bias could not be excluded, it is likely that these improvements can be attributed to the lower treatment burdens of the galenic formulations of the drugs considered. Further investigation is required to confirm these findings and to determine whether new galenic formulations can improve health outcomes in routine clinical practice.
Introduction
Advances in pharmacotherapy are typically perceived as being related to the availability of new molecular entities or compounds. However, there has been a gradual change in the way many stakeholders think about innovation in light of several scientific publications,Citation1,Citation2 official documents,Citation3,Citation4 and the use of value-based pricing in an increasing number of countries.Citation5 A more holistic view of innovation places less emphasis on developmental considerations, such as creation of new molecules (with whatever degree of structural novelty) and more emphasis on individual patients and society as a whole, with improvements in health outcomes driving research into, and rewards for, pharmaceutical innovation. Such a system assesses the value of new molecules and galenic enhancements using the same terms of reference (ie, health outcomes).
While there is abundant clinical research comparing new molecules with placebo or an active comparator, there has traditionally been a lack of head-to-head comparisons between different galenic formulations of the same active molecule in “real-world” clinical practice. Therefore, there is little information available to describe the effects of new formulations on compliance and persistence despite the important effects of medication-taking behavior on clinical outcomes. Noncompliance with treatment and medical advice may cause accelerated disease, increased outpatient visits, more admissions to hospital, and impaired ability to predict the effectiveness of treatment.Citation6 In addition, increased morbidity and mortality due to noncompliance may increase health care costs.Citation7–Citation10
Compliance is affected by numerous factors, which can be broadly classified as being related to the patient, society, and the treatment.Citation11 Treatment-related factors include the mode of delivery, frequency of administration, and adverse effects.Citation11 Reducing the burden of treatment, by simplifying treatment regimens for example, may have the potential to enhance complianceCitation11 and ultimately the outcomes of treatment.Citation12–Citation14 New formulations often have less complex regimens (eg, less frequent dosing) or more convenient routes of administration (eg, oral instead of intravenous infusion). However, while several studies have shown (for example) that once-daily treatments are associated with higher rates of compliance than more complex regimens,Citation15–Citation18 few studies have directly compared persistence and compliance between galenically different molecular analogs or near-analogs.
Materials and methods
Objective
The objective of the study was to determine whether newer galenic formulations of drugs with lower treatment burdens are associated with better patient compliance and persistence compared with older more burdensome modalities. To explore the potential for new galenic formulations to improve compliance and persistence, we retrospectively reviewed data from the IMS Disease Analyzer database.
Database content and selection of analogs
The Intercontinental Medical Statistics (IMS) Disease Analyzer database includes data collected directly from computers in physicians’ practices in Germany and the UK and provides daily routine information on patients’ diseases and therapies, allowing tracking of prescription history. Each practice transmits patient data to IMS on a monthly basis. The database includes only anonymized data in compliance with applicable data protection legislation. The IMS Disease Analyzer database was reviewed to identify products that had undergone a formulation change with the potential to provide a major benefit for patients, such as improved convenience or reduced treatment burden. Products were considered for inclusion in the study if they were indicated for a condition that was associated with a high disease burden and required long-term treatment, and if their entries in the database included data on the timing and nature of prescriptions. Based on these criteria, three pairs of products were identified, ie, alendronate (Fosamax®) once daily and once weekly, methylphenidate immediate-release (Ritalin®) and extended-release (Concerta®), and a pair of drugs with similar indications but important differences in convenience and dosing instructions (desferrioxamine [Desferal®] and deferasirox [Exjade®]).
Alendronate once daily is indicated for prevention of fractures in men and postmenopausal women with osteoporosis, for treatment of glucocorticoid-induced osteoporosis, and to prevent bone loss in postmenopausal women at risk of osteoporosis.Citation19 In Germany, alendronate once daily is indicated to reduce the risk of new vertebral and hip fractures in postmenopausal women without pre-existing vertebral fractures and for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women not receiving estrogens, and is formulated as a 10 mg oral tablet.Citation20 Alendronate weekly is indicated for prevention of fractures in postmenopausal women with osteoporosis in the UK and Germany and is formulated as a 70 mg oral tablet.Citation21,Citation22 Both alendronate products have restrictive dosing instructions. Tablets must be taken at least 30 minutes before the first food, beverage, or medicinal product of the day with plain water only. Patients must take the tablets with a full glass of water (at least 200 mL) and must not lie down until after their first food of the day. The tablet must be swallowed whole and must not be crushed or chewed.
Immediate-release and extended-release methylphenidate are both indicated for management of attention-deficit hyperactivity disorder (ADHD) in children aged 6 years of age and older.Citation23–Citation25 Immediate-release methylphenidate is formulated as a 10 mg tablet and requires careful dose titration, beginning once or twice daily (eg, at breakfast and lunch) with the dose and frequency increased up to a maximum of 60 mg/day if required.Citation25 A small evening dose may be required if the effects wear off. Extended-release methylphenidate is formulated as an 18 mg, 27 mg, or 36 mg capsule-shaped tablet and must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed. It may be administered with or without food and is taken once daily in the morning.Citation23,Citation24 Doses may be adjusted in 18 mg increments starting with the lowest dose up to a maximum of 54 mg/day.
Desferrioxamine is formulated as a sterile, lyophilized powder for reconstitution in a vial containing 500 mg or 2 g of drug,Citation26 whereas deferasirox is formulated as a dispersible 125 mg, 250 mg, or 500 mg tablet.Citation27 In the UK, desferrioxamine is indicated for treatment of chronic iron overload, primary and secondary hemochromatosis, acute iron poisoning, and aluminum overload, and requires reconstitution before intravenous infusion, intramuscular injection, or subcutaneous infusion (the route of delivery depends on the condition being treated, with an average daily dose of 20–60 mg/kg/day adjusted based on initial monitoring of urinary ferritin).Citation26 Deferasirox is indicated for chronic iron overload due to frequent blood transfusions in patients with beta thalassemia major aged 6 years and older and for treatment of chronic iron overload due to blood transfusions when desferrioxamine therapy is contraindicated or inadequate. It is administered once daily on an empty stomach at least 30 minutes before food, preferably at the same time each day, usually at an initial dose of 20 mg/kg with adjustments in 5–10 mg/kg increments based on monitoring of serum ferritin.Citation27 In Germany, deferasirox is indicated for the management of chronic iron overload due to frequent transfusions in patients with beta thalassemia major over 6 years of age and for the management of chronic transfusional iron overload.Citation28 The tablets are dispersed by stirring in a glass of water or orange or apple juice. Any residue remaining in the glass must be resuspended in a small volume of water or juice and swallowed.
Data retrieval and analysis
Data were retrieved from the IMS Disease Analyzer database. Records were available for patients treated in the UK and Germany. Analyses of alendronate and methylphenidate included patients from the UK and Germany. Analysis of desferrioxamine and deferasirox was restricted to patients from Germany, because complete data were not available for patients receiving these products in the UK. All patients receiving any of the products were included in the analyses.
Patients included in the analysis had to be initiated on the formulation of interest and not received any previous prescription for the same combination of substance and formulation. Patients had to have treatment initiated between January 2003 and December 2007 in order to provide for a follow-up period of at least 2 years at the time of analysis (December 2009). For each patient included in the analysis, information was retrieved from the database to identify the substance, formulation, and dose. Dates of prescriptions, quantity of medication, dosage, and prescription duration were used to calculate compliance and persistence.
Compliance is generally defined as the act of following the treatment recommendations made by the prescriber in terms of dose and frequency of medication.Citation29 It is measured over a period of time and is expressed as a percentage. In our study, compliance was calculated as the sum of the durations of prescribed treatments for an individual patient over a 1-year period. For the chronic conditions considered in our analyses, it was assumed that patients required treatment continuously throughout the study period and that gaps in the prescribing history reflected noncompliance. The 1-year period was selected to capture sufficient prescription data without biasing the results by including patients who had stopped using the drug (as would have been the case if longer time periods had been used).
Persistence is generally defined as the duration of treatment from initiation until discontinuation and can be reported as a continuous variable (number of days for which the medication was available) or a dichotomous variable (persistent or nonpersistent) at the end of the observation period.Citation29 In our study, treatment periods evaluated for persistence were calculated as the time between the first and last prescription using the quantity prescribed and dosage instruction issued by the doctor. A 2-year time period was used for analysis of persistence to account for patients using the drugs for periods of time greater than the 1-year period used for analysis of compliance. However, due to the recent introduction of deferasirox at the time of analysis, data were not available for 2 years and persistence was therefore calculated over 1 year for both deferasirox and desferrioxamine. As per definition, gaps in prescribed treatment were not taken into account for the analysis of persistence. Patients were considered nonpersistent if they stopped taking the medication for any reason, including switching to another medication or no longer requiring treatment. A patient was defined as having stopped medication if he or she had no current prescription for that medication at the time of analysis.
Results
For alendronate once daily and weekly, data on persistence and compliance were retrieved for 595 and 13,468 patients, respectively, in the UK, and 554 and 8941, respectively, in Germany. For immediate-release and extended-release methylphenidate, data were retrieved for 449 and 590 patients, respectively, in the UK, and 594 and 483, respectively, in Germany. For desferrioxamine and deferasirox, data were retrieved for 518 and 2229 patients, respectively, in Germany.
Compliance
For all three pairs of products, compliance was higher with the newer formulations than with the original agents (). Absolute incremental improvements in compliance over 1 year were +30% in the UK and +26% in Germany for alendronate once weekly vs once daily, +14% in the UK and +19% in Germany for extended-release vs immediate-release methylphenidate, and +15% in Germany for desferrioxamine vs deferasirox. Among patients receiving alendronate once daily, 33% in the UK and 40% in Germany took their medication for 0%–10% of the time during the first year, compared with 10% and 17%, respectively, for alendronate weekly. Higher percentages of patients receiving alendronate weekly (52% in the UK and 33% in Germany) took their medication at least 90% of the time over 1 year, compared with those receiving alendronate once daily (21% in the UK and 14% in Germany). Similarly, 15% of immediate-release methylphenidate recipients in the UK and 39% in Germany took their medication for 0%–10% of the time, compared with 9% and 16%, respectively, for extended-release methylphenidate. Patients receiving extended-release methylphenidate were more likely to take their medication at least 90% of the time over 1 year (46% in the UK and 17% in Germany), compared with patients receiving immediate-release methylphenidate (28% in the UK and 5% in Germany). Among patients receiving desferrioxamine in Germany, 47% took their medication for 0%–10% of the time during the first year, compared with 26% for deferasirox. Similar percentages of German patients receiving deferasirox (16%) and desferrioxamine (14%) took their medication at least 90% of the time over 1 year.
Table 1 Mean compliance over 1 year
Persistence
Persistence was higher for all three newer formulations, compared with the respective older formulations (). Incremental improvements in persistence over 2 years were +9 months in the UK and +8 months in Germany for alendronate once weekly vs once daily, +4 months in the UK and +3 months in Germany for extended-release vs immediate-release methylphenidate, and +2 months in Germany for deferasirox vs desferrioxamine. Among patients receiving alendronate weekly, 63% in the UK and 42% in Germany took their medication for at least 2 years, compared with 22% and 12%, respectively, for alendronate once daily. Patients receiving alendronate weekly were less likely to stop taking their medication during the first 2 months (12% in the UK and 17% in Germany), compared with alendronate once daily (41% in the UK and 54% in Germany). Similarly, 69% of extended-release methylphenidate recipients in the UK and 41% in Germany took their medication for at least 2 years, compared with 42% and 32%, respectively, for immediate-release methylphenidate. The percentage of patients who stopped taking their medication during months 1 or 2 was lower with extended-release methylphenidate (9% in the UK and 25% in Germany) than with immediate-release methylphenidate (18% in the UK and 37% in Germany). Among patients receiving deferasirox in Germany, 31% took their medication for over 2 years, compared with 25% for desferrioxamine. In Germany, fewer patients stopped taking deferasirox (29%) during months 1 and 2, compared with desferrioxamine (38%).
Table 2 Mean persistence over 2 years
Discussion
Our analyses indicate that, for the three selected pairs of products, newer agents with improved galenic formulations were associated with higher rates of compliance and persistence than older formulations. Newer products (alendronate weekly, extended-release methylphenidate, and deferasirox) were associated with incremental improvements in 1-year compliance of between 14% and 30% vs older products (alendronate once daily, immediate-release methylphenidate, and desferrioxamine). The newer products were also associated with higher mean persistence (increments of 2–9 months) compared with the older products. The difference in compliance and persistence between the methylphenidate formulations occurred despite the fact that placebo-controlled studies have indicated that some adverse events (especially insomnia) may be more frequent with longer-acting products.Citation30 Therefore, our findings indicate that the greater convenience of extended-release methylphenidate may outweigh possible disadvantages related to a higher incidence of adverse effects.
The differences in compliance and persistence between deferasirox and desferrioxamine were smaller than the differences between weekly and once-daily alendronate or between extended-release and immediate-release methylphenidate. The smaller difference in persistence may have been related to the shorter assessment period used in patients receiving deferasirox and desferrioxamine (1 year) compared with the other pairs of products (2 years). The smaller difference between deferasirox and desferrioxamine, compared with the differences between weekly and once-daily alendronate, may also have been related to the fact that many patients who require deferasirox or desferrioxamine for beta thalassemia are children who will be assisted by their parents when taking the medication. This assistance may have increased rates of compliance and persistence. However, many patients receiving methylphenidate are young children, so it is unlikely that differences in parental assistance could explain the difference between deferasirox and desferrioxamine, compared with the difference between immediate-release and extended-release methylphenidate.
The higher compliance and persistence associated with the newer formulations might be related to a lower treatment burden compared with the older products. For example, alendronate has restrictive dosing instructions, and the difference in dosing frequency between formulations might result in a lower burden for patients receiving the weekly formulation, compared with daily dosing. Similarly, extended-release methylphenidate is given once daily at breakfast whereas immediate-release methylphenidate is given up to three times a day, requiring children to take the tablets during their school day. Deferasirox is also easier to administer (dispersed in water or fruit juice) than desferrioxamine (reconstituted and infused using a pump for five nights per week).
While the aforementioned causal attribution appears plausible, several limitations of the study should be noted. Our findings indicate that the newer treatments were associated with higher compliance and persistence than the older treatments. However, the possibility that these findings were due to differences between the populations being prescribed each product, rather than to the products themselves, cannot be ruled out. No data are available to determine whether there were meaningful differences between the patient populations. Because this was a retrospective study, the patients were not randomized to the various treatment groups and there may have been differences between the populations receiving the newer vs the older formulations. For example, physicians may have been more inclined to prescribe newer formulations to certain patients (eg, those with more severe disease) than to others (selection bias). Having said that, it appears unclear in which direction (overestimation or underestimation) this bias would work. Further, our analysis could not adjust for the influence of industry-driven promotion and disease education, which may also affect the uptake of newer treatments.
Although the IMS database provides a representative sample of German and UK patient populations, it should also be noted that our findings may not be applicable to other countries. It is also important to note that our assessments of compliance and persistence were based on the number of prescriptions and did not take account of whether patients actually filled the prescription or took the medication. Therefore, our analyses may have overestimated both compliance and persistence. Assuming that both arms of each pair-wise comparison were affected equally by a potential overestimation, this would not have affected the incremental analysis. However, as mentioned before, any potential selection effects are unclear or unknown.
While our study did not directly assess the burden associated with each treatment, several other studies have indicated that newer formulations are associated with improved patient satisfaction and quality of life, compared with older formulations. For example, patients receiving deferasirox have been shown to have improved satisfaction and quality of life, lower levels of anxiety and depression, and higher compliance, compared with previous treatments.Citation31–Citation38 In addition, a study of patients receiving iron chelating therapy (injected or oral) showed that four variables were significant predictors of never thinking about stopping treatment, ie, age, perceived effectiveness of therapy, burden of therapy, and low incidence of adverse effects.Citation39 Studies have also shown that weekly or monthly dosing with bisphosphonates (alendronate or ibandronate) is preferred by many patients, compared with daily dosing,Citation40–Citation42 and that weekly alendronate is associated with higher compliance than daily bisphosphonates.Citation43
If reformulation of a product results in improved compliance and persistence, it would be reasonable to hypothesize that there might be an associated improvement in efficacy. A small number of studies have compared extended-release and immediate-release methylphenidate, including two that showed that switching from immediate-release to extended-release methylphenidate improved symptom control in children and adolescents with ADHD.Citation44,Citation45 There was also an improvement in compliance after the switch in one of these studies;Citation44 no data on compliance were provided in the published results from the other study.Citation45 In addition, a study of children with ADHD who were poorly compliant with immediate-release methylphenidate showed that, after switching to extended-release methylphenidate, 72% of children had good compliance.Citation46 This improvement was accompanied by improvements in symptom control. However, a randomized study in children with ADHD showed that the two methylphenidate formulations had similar efficacy, despite a slightly higher completion rate with extended-release methylphenidate (81%) than with the immediate-release formulation (75%).Citation47 In contrast, another study in children with ADHD showed that extended-release methylphenidate was more effective than immediate-release methylphenidate, but there was no difference in discontinuation rates during the study.Citation48 Overall, these studies indicate that switching from immediate-release to extended-release methylphenidate may improve compliance, but it remains unclear whether increases in compliance or persistence translate into improved efficacy in routine clinical practice.
Several studies have compared deferasirox and desferrioxamine. A study in patients with transfusional iron overload due to sickle cell disease showed that deferasirox and desferrioxamine resulted in similar reductions in liver iron concentration.Citation49 Discontinuation rates were similar between deferasirox (11.4%) and desferrioxamine (11.1%).Citation49 Efficacy (reduction in liver iron concentration) was also similar between deferasirox and desferrioxamine in a study of patients with transfusional iron overload due to thalassemia, although no information on discontinuation rates was provided in the publication from that study.Citation50
Comparisons of alendronate weekly (70 mg or 35 mg once weekly) and once daily (10 mg or 5 mg) have shown that the two products are therapeutically equivalent and have similar safety and tolerability.Citation51–Citation53 However, there have been no studies comparing the efficacy of the two formulations in a “real-world” setting.
Conclusion
Our analysis indicates that the reduced treatment burdens attributed to new galenic formulations which we evaluated against their older counterparts are associated with better compliance and persistence. Further investigation, with different study designs and the inclusion of additional control variables, is required to confirm these findings and to evaluate the extent to which new galenic formulations can ultimately improve health outcomes in routine clinical practice.
Disclosure
This study was funded by Novartis Pharma AG, Basel, Switzerland. M-MB and AGM are employees of Novartis. The authors were assisted in the preparation of the manuscript by Paul Hutchin, a professional medical writer contracted to ACUMED® and funded by Novartis. Editorial assistance was provided by Helen Venables (ACUMED®), funded by Novartis.
References
- StaffordRSWagnerTHLavoriPWNew, but not improved? Incorporating comparative-effectiveness information into FDA labelingN Engl J Med20093611230123319675326
- StiglitzJEJayadevAMedicine for tomorrow: some alternative proposals to promote socially beneficial research and development in pharmaceuticalsJournal of Generic Medicines20107217226
- German Pharmaceutical SocietyBlumeHBrauerKDingermannTon behalf of the expert group “drug innovation”Criteria for the evaluation of drug innovations. Position paperPharmazeutische Zeitung2005150Suppl142 Available at: http://www.dphg.de/includes/upload/DPhG-Positionspapier.pdf. Accessed July 12, 2011. German.
- KennedyIAppraising the value of innovation and other benefits a short study for NICE2009 Available from: http://www.nice.org.uk/media/98F/5C/KennedyStudyFinalReport.pdf. Accessed July 5, 2010.
- WillisMPerssonUZoellnerYGradlBReducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa[R]) in SwedenAppl Health Econ Health Policy2010837738621043539
- AbbottJDoddMBiltonDWebbAKTreatment compliance in adults with cystic fibrosisThorax1994491151208128399
- GorenoiVSchonermarkMPHagenAInterventions for enhancing medication compliance/adherence with benefits in treatment outcomesGMS Health Technol Assess20083 Doc14.
- MarceauCLemiereCBerbicheDPerreaultSBlaisLPersistence, adherence, and effectiveness of combination therapy among adult patients with asthmaJ Allergy Clin Immunol200611857458116950273
- YangWChangJKahlerKHEvaluation of compliance and health care utilization in patients treated with single pill vs free combination antihypertensivesCurr Med Res Opin2010262065207620629600
- BrixnerDIYeXChuTCBlumentalsWAHassaneinTITreatment persistence in and cost of therapy for patients with chronic hepatitis C: peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirinAm J Health Syst Pharm2009662171217819966085
- LareauSCYawnBPImproving adherence with inhaler therapy in COPDInt J Chron Obstruct Pulmon Dis2010540140621191434
- ElliottWJImproving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapyJ Clin Hypertens (Greenwich)20091137638219583634
- RestrepoRDAlvarezMTWittnebelLDMedication adherence issues in patients treated for COPDInt J Chron Obstruct Pulmon Dis2008337138418990964
- SirisESSelbyPLSaagKGBorgstromFHeringsRMSilvermanSLImpact of osteoporosis treatment adherence on fracture rates in North America and EuropeAm J Med2009122Suppl 2S3S1319187810
- BourbeauJBartlettSJPatient adherence in COPDThorax20086383183818728206
- PriceDRobertsonABullenKRandCHorneRStaudingerHImproved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label studyBMC Pulm Med201010120051135
- RaboudJLiMWalmsleySOnce daily dosing improves adherence to antiretroviral therapyAIDS Behav2010 [Epub ahead of print].
- YentzerBAAdeRAFountainJMSimplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trialCutis20108610310820919606
- Fosamax SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/1175/SPC/Fosamax/#INDICATIONS. Accessed June 15, 2011.
- Gelbe Liste PharmindexFosamax2011 Available from: http://www.gelbe-liste.de/pharmindex/praeparat/bi/fosamax-10mg-tbl-msd-sharp-dohme-gmbh/#top. Accessed April 4, 2011.
- Fosamax weekly SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/4115/SPC/Fosamax+Once+Weekly+70mg+Tablets/#INDICATIONS. Accessed June 15, 2011.
- Gelbe Liste Pharmindex [Fosamax once weekly].2011 Available from: http://www.gelbe-liste.de/pharmindex/praeparat/bi/fosamax-einmal-woechentlich-70mg-tbl-msd-sharp-dohme-gmbh/. Accessed April 4, 2011. Password-protected – access restricted to registered health care professionals.
- Concerta 18–36 mg SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/8382/SPC/Concerta+XL+18+mg+-+36+mg+prolonged+release+tablets/. Accessed June 15, 2011.
- Concerta 27 mg SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/19549/SPC/Concerta+XL+27+mg+prolonged-release+tablets/#INDICATIONS. Accessed June 15, 2011.
- Ritalin SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/1316/SPC/Ritalin/#FORM. Accessed January 24, 2011.
- Desferal SmPCSummary of product characteristics2010 Available from: http://www.medicines.org.uk/EMC/medicine/2666/SPC/Desferal+Vials%2c+500mg+or+2g/#FORM. Accessed June 15, 2011.
- Exjade SmPCSummary of product characteristics2011 Available from: http://www.medicines.org.uk/EMC/medicine/18805/SPC/EXJADE+125+mg%2c+250mg%2c+500mg+dispersible+tablets/#FORM. Accessed June 15, 2011.
- Gelbe Liste PharmindexExjade2011 Available from: http://www.gelbe-liste.de/pharmindex/praeparat/bi/exjade-125-mg-tabletten-zur-herstellung-einer-suspension-zum-einnehmen-novartis-pharma-gmbh/. Accessed April 4, 2011.
- CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health200811444718237359
- MerkelRLJrKuchibhatlaASafety of stimulant treatment in attention deficit hyperactivity disorder: part IExpert Opin Drug Saf2009865566819785509
- PorterJBAthanasiou-MetaxaMBowenDKImproved patient satisfaction, adherence and health-related quality of life with deferasirox (Exjade®) in beta-thalassemia patients previously receiving other iron chelation therapiesBlood2009114980981
- YamashitaRSobotaATrachtenbergFThe impact of the child with thalassemia on the family: parental assessment by child health questionnaireBlood2009114558
- MednickLYuSTrachtenbergFSymptoms of anxiety and depression among teens and adults in the thalassemia longitudinal cohort studyBlood200911423123219589929
- PorterJBBowdenDGanserASatisfaction and adherence significantly improves in patients with beta-thalassemia and myelodysplastic syndromes treated with deferasiroxBlood2008112472
- VichinskyEPakbazZOnyekwereOPatient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trialActa Haematol200811913314118408362
- OsborneRHDe AbreuLRDaltonAQuality of life related to oral versus subcutaneous iron chelation: a time trade-off studyValue Health20071045145617970927
- CappelliniMDBejaouiMAgaogluLProspective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemiaClin Ther20072990991717697909
- DeleaTESofryginOThomasSKBaladiJFPhatakPDCoatesTDCost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspectivePharmacoeconomics20072532934217402805
- RofailDAbetzLVialaMGaitCBaladiJFPayneKSatisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrumentValue Health20091210911718637142
- BockOFelsenbergDBisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practiceClin Interv Aging2008327929718686751
- KendlerDKungAWFuleihanGPatients with osteoporosis prefer once weekly to once daily dosing with alendronateMaturitas20044824325115207890
- SimonJALewieckiEMSmithMEPetruschkeRAWangLPalmisanoJJPatient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover studyClin Ther2002241871188612501880
- CramerJAAmonkarMMHebbornAAltmanRCompliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurr Med Res Opin2005211453146016197664
- HoarePRemschmidtHMedoriR12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPHEur Child Adolesc Psychiatry20051430530916220214
- RemschmidtHHoarePEttrichCSymptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label studyEur Child Adolesc Psychiatry20051429730416220213
- ChouWJChouMCTzangRFBetter efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypesPsychiatry Clin Neurosci20096316717519335386
- BiedermanJMickEOSurmanCComparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorderBMC Psychiatry200774917868455
- SteeleMWeissMSwansonJWangJPrinzoRSBinderCEA randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorderCan J Clin Pharmacol200613e50e6216456216
- VichinskyEOnyekwereOPorterJA randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell diseaseBr J Haematol200713650150817233848
- PigaAGalanelloRForniGLRandomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadHaematologica20069187388016818273
- LuckeyMMGilchristNBoneHGTherapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosisObstet Gynecol200310171172112681875
- SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study groupAging (Milano)20001211210746426
- UchidaSTaniguchiTShimizuTTherapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyJ Bone Miner Metab20052338238816133688